Clinical characteristics of liver transplant recipients with HCC according to different donor-recipient matched-patterns based on sex after PSM
| Variables | Female donor and female recipient (F-F) n = 84 | Male donor and male recipient (M-M) n = 168 | Male donor and female recipient (M-F) n = 168 | Female donor and male recipient (F-M) n = 168 | P value |
|---|---|---|---|---|---|
| Donor age | 0.49 | ||||
| < 50 y | 48 (57.14%) | 87 (51.79%) | 93 (55.36%) | 101 (60.12%) | |
| ≥ 50 y | 36 (42.86%) | 81 (48.21%) | 75 (44.64%) | 67 (39.88%) | |
| Donor type | 0.57 | ||||
| DBD | 48 (57.14%) | 96 (57.14%) | 97 (63.69%) | 107 (57.74%) | |
| DCD | 36 (42.86%) | 72 (42.86%) | 71 (36.31%) | 61 (42.26%) | |
| ABO blood incompatibility | 0.46 | ||||
| Incompatible | 2 (2.38%) | 7 (4.17%) | 3 (1.79%) | 3 (1.79%) | |
| Compatible | 82 (97.62%) | 161 (95.83%) | 165 (98.21%) | 165 (98.21%) | |
| Recipient age | 0.45 | ||||
| < 50 y | 29 (34.52%) | 53 (31.55%) | 67 (39.88%) | 61 (36.31%) | |
| ≥ 50 y | 55 (65.48%) | 115 (68.45%) | 101 (60.12%) | 107 (63.69%) | |
| Hypertension | 0.62 | ||||
| No | 80 (95.24%) | 153 (91.07%) | 154 (91.67%) | 157 (93.45%) | |
| Yes | 4 (4.76%) | 15 (8.93%) | 14 (8.33%) | 11 (6.55%) | |
| Diabetes | 0.29 | ||||
| No | 78 (92.86%) | 153 (91.07%) | 160 (95.24%) | 151 (89.88%) | |
| Yes | 6 (7.14%) | 15 (8.93%) | 8 (4.76%) | 17 (10.12%) | |
| HBsAg | 0.99 | ||||
| Negative | 16 (19.05%) | 33 (19.64%) | 33 (19.64%) | 33 (19.64%) | |
| Positive | 68 (80.95%) | 135 (80.36%) | 135 (80.36%) | 135 (80.36%) | |
| Child-Pugh classification | 0.69 | ||||
| A | 18 (21.43%) | 26 (15.48%) | 33 (19.64%) | 36 (21.43%) | |
| B | 27 (32.14%) | 71 (42.26%) | 64 (38.10%) | 64 (38.10%) | |
| C | 39 (46.43%) | 71 (42.26%) | 71 (42.26%) | 68 (40.48%) | |
| Any TACE | 0.98 | ||||
| No | 74 (88.10%) | 148 (88.10%) | 146 (86.90%) | 148 (88.10%) | |
| Yes | 10 (11.90%) | 20 (11.90%) | 22 (13.10%) | 20 (11.90%) | |
| Any RFA | 0.97 | ||||
| No | 79 (94.05%) | 160 (95.24%) | 160 (95.24%) | 159 (94.64%) | |
| Yes | 5 (5.95%) | 8 (4.76%) | 8 (4.76%) | 9 (5.36%) | |
| MELD | 14 (9–31) | 13 (9–30) | 14.5 (9–30) | 15 (9–30.5) | 0.98 |
| Beyond Milan criteria | 0.77 | ||||
| No | 54 (64.29%) | 104 (61.90%) | 112 (66.67%) | 104 (61.90%) | |
| Yes | 30 (35.71%) | 64 (38.10%) | 56 (33.33%) | 64 (38.10%) | |
| Beyond Hangzhou criteria | 0.74 | ||||
| No | 71 (84.52%) | 143 (85.12%) | 149 (88.69%) | 145 (86.31%) | |
| Yes | 13 (15.48%) | 25 (14.88%) | 19 (11.31%) | 23 (13.69%) | |
| Largest tumor size | 0.49 | ||||
| < 3 cm | 32 (38.10%) | 57 (33.93%) | 70 (41.67%) | 72 (42.86%) | |
| 3–5 cm | 37 (44.05%) | 70 (41.67%) | 70 (41.67%) | 64 (38.10%) | |
| > 5 cm | 15 (17.86%) | 41 (24.40%) | 28 (16.67%) | 32 (19.05%) | |
| Tumor number | 0.97 | ||||
| Single | 54 (64.29%) | 113 (67.26%) | 111 (66.07%) | 112 (66.67%) | |
| Multiple | 30 (35.71%) | 55 (32.74%) | 57 (33.93%) | 56 (33.33%) | |
| Microsatellite | 0.65 | ||||
| No | 77 (91.67%) | 156 (92.86%) | 152 (90.48%) | 158 (94.05%) | |
| Yes | 7 (8.33%) | 12 (7.14%) | 16 (9.52%) | 10 (5.95%) | |
| Cold ischemia time (h) | 6.5 (4.6–8.0) | 6.0 (4.4–7.4) | 6.0 (4.5–7.7) | 6.0 (4.6–7.5) | 0.57 |
| Operative time (h) | 6.8 (5.6–8.2) | 6.8 (5.6–8.0) | 6.9 (5.9–8.2) | 7.0 (6.0–8.0) | 0.89 |
| Operative bleeding (mL) | 750 (400–1500) | 800 (500–1500) | 1000 (600–1500) | 1000 (500–1500) | 0.27 |
| Salvage LT | 0.85 | ||||
| No | 73 (86.90%) | 150 (89.29%) | 151 (89.88%) | 152 (90.48%) | |
| Yes | 11 (13.10%) | 18 (10.71%) | 17 (10.12%) | 16 (9.52%) |
PSM, propensity score matching; LT, liver transplantation; BMI, body mass index; MELD, model for end-stage liver disease; CHILD, Child-Pugh; DBD, donation after brain death; DCD, donation after circulatory death; DBCD, donation after brain and cardiac death; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization.